ConductScience.org, home

Paper36968218

Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial.

Seidensticker M and 18 others. JHEP Rep, 2023. Cited by 14 papers, by iCite.

Cite this record

ConductScience Library. Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial. Papers, record 36968218. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36968218

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial.
PubMed
Journal
JHEP Rep
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
14
iCite
Relative citation ratio, by iCite
1.54
iCite
Revised in PubMed
2023-03-28
PubMed

Authors19

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Seidensticker MMax
2Öcal OOsman
3Schütte KKerstin
4Malfertheiner PPeter
5Berg TThomas
6Loewe CChristian
7Klümpen HJHeinz Josef
8van Delden OOtto
9Ümütlü MRMuzaffer Reha
10Ben Khaled NNajib
11de Toni ENEnrico Narciso
12Seidensticker RRicarda
13Aghdassi AAli
14Tran AAlbert
15Bronowicki JPJean-Pierre
16Peynircioglu BBora
17Sangro BBruno
18Pech MMaciej
19Ricke JJens

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01126645Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver CancerDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References19

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132352320IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.Future Oncol2020https://conductscience.org/library/papers/32352320PubMed
233103093Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma.JHEP Rep2020https://conductscience.org/library/papers/33103093PubMed
317522506A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.Ann Surg2007https://conductscience.org/library/papers/17522506PubMed
422004366Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis.J Gastroenterol Hepatol2012https://conductscience.org/library/papers/22004366PubMed
534801630BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.J Hepatol2022https://conductscience.org/library/papers/34801630PubMed
634243077Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial).Eur J Cancer2021https://conductscience.org/library/papers/34243077PubMed
717133492Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.Hepatology2006https://conductscience.org/library/papers/17133492PubMed
829503247Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial.Lancet Gastroenterol Hepatol2018https://conductscience.org/library/papers/29503247PubMed
923023956Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria.Br J Surg2012https://conductscience.org/library/papers/23023956PubMed
1031421157Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.J Hepatol2019https://conductscience.org/library/papers/31421157PubMed
1118650514Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008https://conductscience.org/library/papers/18650514PubMed
1221574174Effect of vitamin K2 on the recurrence of hepatocellular carcinoma.Hepatology2011https://conductscience.org/library/papers/21574174PubMed
1319095497Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.Lancet Oncol2009https://conductscience.org/library/papers/19095497PubMed
1422634125A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma.J Hepatol2012https://conductscience.org/library/papers/22634125PubMed
1524728665Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study.J Gastroenterol2015https://conductscience.org/library/papers/24728665PubMed
1626361969Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.Lancet Oncol2015https://conductscience.org/library/papers/26361969PubMed
1725064436Increased survival in hepatocellular carcinoma with iodine-125 implantation plus radiofrequency ablation: a prospective randomized controlled trial.J Hepatol2014https://conductscience.org/library/papers/25064436PubMed
1829628281EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.J Hepatol2018https://conductscience.org/library/papers/29628281PubMed
1925284802Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma.Hepatology2015https://conductscience.org/library/papers/25284802PubMed

Download CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.

PMIDTitleJournalYearIn PapersSource
42882822Adjuvant and Perioperative Systemic Therapy for Resectable Hepatocellular Carcinoma: Evidence, Biological Rationale, and Trial Design.Cancers (Basel)2026https://conductscience.org/library/papers/42882822PubMed
41892200The State of the Art in Combination Locoregional and Systemic Treatment Strategies for Hepatocellular Carcinoma: Recent Advancements and Future Horizons.Curr Oncol2026https://conductscience.org/library/papers/41892200PubMed
41695324Traditional Cox regression outperforms large language models in predicting long-term progression of intermediate to advanced hepatocellular carcinoma.Front Oncol2026https://conductscience.org/library/papers/41695324PubMed
41263849
Individualised dosimetry for holmium-166 RE in patients with unresectable hepatocellular carcinoma; a multi-centre, interventional, non-randomised, non-comparative, open label, phase II study: RHEPaiR.
BMJ Open2025https://conductscience.org/library/papers/41263849PubMed
40573279The Efficacy of Combined Use of Huaier Granules in the Treatment of Primary Liver Cancer: An Updated Systematic Review and Meta-Analysis.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/40573279PubMed
40568833Sorafenib with or without co-interventions for hepatocellular carcinoma.Cochrane Database Syst Rev2025https://conductscience.org/library/papers/40568833PubMed
40445470Modern therapeutic approaches for hepatic tumors: progress, limitations, and future directions.Discov Oncol2025https://conductscience.org/library/papers/40445470PubMed
39759148Bibliometric study on the utilization of sorafenib in hepatocellular carcinoma.Front Oncol2024https://conductscience.org/library/papers/39759148PubMed
39579154Evaluation of a deformable image registration algorithm for image-guided thermal ablation of liver tumors on clinically acquired MR-temperature maps.Med Phys2025https://conductscience.org/library/papers/39579154PubMed
39561966Hepatocellular carcinoma systemic treatment update: From early to advanced stage.Biomed J2025https://conductscience.org/library/papers/39561966PubMed
39143267Accuracy of 3D real-time MRI temperature mapping in gel phantoms during microwave heating.Eur Radiol Exp2024https://conductscience.org/library/papers/39143267PubMed
38405324Systemic Drugs for Hepatocellular Carcinoma: What Do Recent Clinical Trials Reveal About Sequencing and the Emerging Complexities of Clinical Decisions?J Hepatocell Carcinoma2024https://conductscience.org/library/papers/38405324PubMed
37568804Early-Stage HCC Percutaneous Locoregional Management: East versus West Perspectives.Cancers (Basel)2023https://conductscience.org/library/papers/37568804PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36968218

GET https://conductscience.org/api/papers/v1/36968218/authors